Emerging Growth Patterns Driving Expansion in the Epitranscriptomic Therapies Market

The field of epitranscriptomic therapies is rapidly advancing, showing significant promise for the future of personalized medicine and cancer treatment. With increasing research efforts and technological innovations, this market is set to undergo substantial growth. Let's explore the current market size, key players, prevailing trends, and the main segments shaping this evolving industry.

Projected Growth and Market Size of the Epitranscriptomic Therapies Market
The epitranscriptomic therapies market is anticipated to experience remarkable expansion, reaching a valuation of $4.2 billion by 2030. This growth reflects a strong compound annual growth rate (CAGR) of 21.9%. Several critical factors contribute to this increase, including heightened investments in RNA-based therapeutics, a growing demand for more precise cancer treatments, and the broader adoption of personalized medicine. Additionally, increased clinical trial activities focused on epitranscriptomics and greater regulatory engagement surrounding novel RNA therapies are key drivers. Important market trends during this period involve the development of extensive epitranscriptomic drug pipelines, the enhanced use of RNA modification profiling tools, the growth of combination therapies, greater integration of bioinformatics in treatment design, and an intensified focus on precision medicine applications.

Download a free sample of the epitranscriptomic therapies market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33108&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Key Players Driving Innovation in the Epitranscriptomic Therapies Market
The market features a number of leading companies actively involved in epitranscriptomic therapies. Some of the most prominent players include AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

A notable collaboration was announced in June 2025, when US-based biotechnology firm Synfini Inc. partnered with O2nix Bio Inc. to co-develop new cancer treatments targeting FTSJ1, a tRNA-modifying enzyme involved in the survival of metastatic cancer cells. This alliance combines O2nix Bio's expertise in RNA epitranscriptomics and cancer metastasis biology with Synfini's AI-powered drug discovery platform, which integrates computational design, automated synthesis, and testing. O2nix Bio specializes in RNA biology and the epitranscriptomic mechanisms that drive cancer metastasis.

View the full epitranscriptomic therapies market report:
https://www.thebusinessresearchcompany.com/report/epitranscriptomic-therapies-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Emerging Trends Highlighted in the Epitranscriptomic Therapies Market
A growing trend among key players is the formation of strategic partnerships designed to accelerate innovation in RNA-modifying cancer therapies. Such collaborations allow companies to pool resources, share expertise, and reduce risks while speeding up progress and enhancing market competitiveness. These partnerships are vital for driving forward advanced therapeutic developments in this field.

For example, in January 2026, UK-based STORM Therapeutics Ltd. joined forces with US-based Alida Biosciences Inc. to push forward cancer therapies focused on epitranscriptomic mechanisms. This collaboration seeks to integrate AlidaBio's EpiPlex and EpiScout platforms with STORM's clinical trials of STC-15, a first-in-class METTL3 inhibitor. The partnership aims to discover and validate m6A RNA modification biomarkers to predict patient responses and optimize therapeutic approaches, combining cutting-edge drug development with advanced RNA profiling.

Core Segments Defining the Global Epitranscriptomic Therapies Market
The global epitranscriptomic therapies market is categorized into several primary segments to provide a detailed understanding:

1) Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) Route of Administration: Injectable; Oral; Other Routes of Administration
3) Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) End-User: Hospitals; Research Institutes; Pharmaceutical and Biotechnology Companies; Other End-Users

Within these broad segments are several subcategories:
- Small Molecule Inhibitors include Methyltransferase Inhibitors, Demethylase Inhibitors, Reader Protein Inhibitors, Writer Enzyme Inhibitors, and Eraser Enzyme Inhibitors.
- Ribonucleic Acid Modifying Enzymes cover Methyltransferase Enzymes, Demethylase Enzymes, Pseudouridine Synthase Enzymes, Adenosine Deaminase Enzymes, and Cytidine Deaminase Enzymes.
- Antisense Oligonucleotides consist of Gapmer Oligonucleotides, Splice Modulating Oligonucleotides, Translation Blocking Oligonucleotides, Exon Skipping Oligonucleotides, and Gene Expression Silencing Oligonucleotides.
- Other Therapy Types include RNA Interference-Based Therapies, Messenger RNA Editing Therapies, Epitranscriptomic Vaccine Platforms, Gene Regulation Modulation Therapies, and Combination Epitranscriptomic Therapies.

These segments collectively outline the diverse and rapidly evolving landscape of the epitranscriptomic therapies market as it moves toward more precise and effective treatment solutions.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.